阅读说明：本技术 用于制备具有降低的变应原性的gos的方法 (Process for the preparation of GOS with reduced allergenicity ) 是由 D·A·格罗恩韦尔德 B·J·H·凯珀斯 B·J·M·德尔辛 L·曹 于 2018-06-26 设计创作，主要内容包括：本发明涉及营养成分领域,特别是涉及用于生产低变应原性低聚半乳糖(GOS)的方法及其在食品和饮品中的用途。本发明提供了衍生自土生隐球菌(最近重命名为土生蝶孢银耳)的β-半乳糖苷酶(EC 3.2.1.23)在生产低变应原性GOS制剂中的用途,该低变应原性GOS制剂在受试者中诱导过敏反应的能力降低。(The present invention provides the use of β -galactosidase (EC3.2.1.23) derived from Cryptococcus terrestris (recently renamed Tremella terrestris) for the production of hypoallergenic GOS preparations having a reduced ability to induce allergic reactions in a subject.)

1. use of β -galactosidase (EC3.2.1.23) derived from Cryptococcus terrestris, recently renamed Tremella terrestris, for the production of a hypoallergenic Galactooligosaccharide (GOS) preparation, wherein the GOS preparation has a reduced ability to induce an (IgE-mediated) allergic reaction in a subject compared to a GOS preparation obtained by transgalactosylating lactose with β -galactosidase derived from Bacillus circulans or derived from Aspergillus oryzae.

2. The use according to claim 1, wherein the subject is known to have hypersensitivity to, or an increased chance of having hypersensitivity to, a GOS preparation obtained by transgalactosylating lactose with bacillus circulans or aspergillus oryzae.

3. A hypoallergenic GOS preparation obtainable by transgalactosylation of lactose with β -galactosidase (ec3.2.1.23) derived from cryptococcus terreus, recently renamed tremella terrestris, for use in at least partially preventing (IgE-mediated) allergic reactions in a subject.

4. A hypoallergenic GOS preparation for use according to claim 3, wherein the subject is known to have an increased chance of, or to be hypersensitive to, GOS preparations obtained by transgalactosylation of lactose using β -galactosidase derived from bacillus circulans or from aspergillus oryzae.

5. A hypoallergenic GOS preparation obtainable by transgalactosylation of lactose using β -galactosidase (ec3.2.1.23) derived from cryptococcus terreus, recently renamed tremella terrestris, for use in a nutritional composition for a subject known to have hypersensitivity, or an increased chance of having hypersensitivity, to a GOS preparation obtained by transgalactosylation of lactose using bacillus circulans or aspergillus oryzae.

6. A method for at least partially preventing hypersensitivity of a subject to a GOS preparation, the method comprising administering to the subject a (hypoallergenic) nutritional composition comprising a hypoallergenic GOS preparation obtainable by transgalactosylation of lactose using β -galactosidase (EC3.2.1.23) derived from cryptococcus terrestris (recently renamed tremella terrestris).

7. The use according to claim 1 or claim 2, the composition for use according to claim 3, claim 4 or claim 5, or the method according to claim 6, wherein the β -galactosidase is derived from the strain cryptococcus terreus MM13-F2171 (accession No.: NITE BP-02177) or APC-6431 (accession No.: NITE BP-02178).

8. The use according to claim 1 or claim 2, the composition for use according to claim 3, claim 4 or claim 5, or the method according to claim 6, wherein the β -galactosidase comprises an amino acid sequence according to any one of SEQ ID NOs 1,2, 3 or 4, or an amino acid sequence which is at least 80%, preferably at least 85%, more preferably at least 90%, even more preferably at least 95%, yet even more preferably at least 97%, and most preferably at least 98% identical to any one of SEQ ID NOs 1,2, 3 or 4.

9. The use, composition for use, or method according to any one of the preceding claims, wherein the hypoallergenic GOS preparation scores lower in a skin prick test of the subject and/or in a basophil activation test performed on a blood sample isolated from the subject, when compared to a GOS preparation obtained by transgalactosylating lactose with bacillus circulans or aspergillus oryzae β -galactosidase.

10. The use, composition for use, or method according to any one of the preceding claims, wherein the subject is of southeast asian origin.

11. The use, composition for use, or method according to any one of the preceding claims, wherein the subject is an adult, adolescent or child, preferably a subject of age 18 months or older.

12. A nutritional composition comprising (i) a hypoallergenic GOS preparation obtainable by transgalactosylating lactose with β -galactosidase (EC3.2.1.23) derived from Cryptococcus terrestris, and (ii) at least one further ingredient selected from the group consisting of a hypoallergenic or non-allergenic protein source, preferably a protein hydrolysate, preferably a non-allergenic protein hydrolysate, free amino acids, probiotics, LC-PUFAs, and carbohydrates such as lactose, sucrose, starch or maltodextrin.

13. A method for providing a hypoallergenic nutritional composition, the method comprising (i) contacting a lactose feed with β -galactosidase (EC3.2.1.23) derived from cryptococcus terreus to provide a hypoallergenic Galactooligosaccharide (GOS) formulation, and (ii) formulating the hypoallergenic GOS formulation into a hypoallergenic nutritional composition together with at least one other hypoallergenic or non-allergenic ingredient.

14. The method of claim 13, wherein the at least one other hypoallergenic or non-allergenic component is selected from the group consisting of a non-allergenic protein hydrolysate, a hydrolysate substantially free of allergenic protein, and a hypoallergenic protein source.

15. A hypoallergenic nutritional composition obtainable by the method according to claim 13 or 14.

16. The method according to claim 13 or claim 14, or the composition according to claim 12 or claim 15, wherein the nutritional composition is a MUM composition for pregnant women, an elongated milk powder, a follow-up formula, or an infant formula.

17. The method according to claim 13 or claim 14, or the composition according to claim 12 or claim 15, wherein the β -galactosidase (EC3.2.1.23) derived from cryptococcus terreus (recently renamed Tremella terreus) is the β -galactosidase (EC3.2.1.23) derived from cryptococcus terreus strain MM13-F2171 (accession No.: NITE BP-02177) or APC-6431 (accession No.: NITE BP-02178).

18. The method according to claim 13 or claim 14, or the composition according to claim 12 or claim 15, wherein the β -galactosidase derived from cryptococcus terreus (EC3.2.1.23) comprises an amino acid sequence according to any one of SEQ id nos 1 to 4, or an amino acid sequence which is at least 80%, preferably at least 85%, more preferably at least 90% identical to said amino acid sequence.